Stock LIPO LIPELLA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Market Closed - Nasdaq
Other stock markets
 01:30:00 22/06/2024 am IST 		5-day change 1st Jan Change
0.57 USD -11.49% Intraday chart for Lipella Pharmaceuticals Inc. -16.16% -44.12%
31/05 Lipella Pharmaceuticals Inc. Announces Completion of Site Initiation Visit for Phase 2A Trial of LP-310 in Oral Lichen Planus CI
09/05 Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
AQ
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
AQ
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
AQ
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
AQ
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
AQ
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
AQ
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
AQ
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
AQ
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
AQ
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease
PR
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
PR
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
PR
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
AQ
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
PR
Lipella Pharmaceuticals Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology
AQ
Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology
PR
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite
PR
Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent
PR
Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIPO Stock
  4. News Lipella Pharmaceuticals Inc.
  5. Press Releases